Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

This study is testing whether empagliflozin (an SGLT2 inhibitor, a type of diabetes medication known for its anti-inflammatory effects), can improve symptoms of major depressive disorder (MDD) when added to standard antidepressant treatment. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with major depressive disorder (MDD) confirmed by a psychiatric interview - Your depression is at least moderately severe (based on a standard rating scale) **You may NOT be eligible if...** - You have bipolar disorder, cyclothymia, schizoaffective disorder, schizophrenia, or other psychotic conditions - You have type 1 diabetes or are at very high risk for diabetic ketoacidosis - You have significant kidney or liver disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.